Article
American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil
Registro en:
VASCONCELLOS, Érica de Camargo Ferreira e et al. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. Journal of the American Geriatrics Society, v. 58, n. 3, p.614-616, Mar. 2010.
0002-8614
10.1111/j.1532-5415.2010.02747.x
1532-5415
Autor
Vasconcellos, Érica de Camargo Ferreira e
Schubach, Armando de Oliveira
Rosalino, Cláudia Maria Valete
Coutinho, Renata de Souza
Silva, Fátima Conceição
Salgueiro, Mariza de Matos
Lyra, Marcelo Rosandiski
Coutinho, Rilza Beatriz Azeredo
Pimentel, Maria Inês Fernandes
Mortari, Sergio Roberto
Madeira, Maria de Fátima
Quintella, Leonardo Pereira
Baptista, Cibele
Marzochi, Mauro Célio de Almeida
Resumen
American tegumentary leishmaniasis (ATL) is a disease affecting the skin and mucosae caused by protozoans of the genus Leishmania transmitted by the bite of female sandflies. Cutaneous leishmaniasis (CL) presents mainly as skin ulcers at exposed body sites. Mucosal leishmaniasis (ML) manifests as chronic and destructive lesions of the nasal, oral, pharyngeal, and laryngeal tissues.1 Pentavalent antimonials are the first-line treatment for ATL. Reports of pentavalent antimonial toxicity include renal tubular dysfunction; cardiac, hepatic, pancreatic, and hematological alterations; and even death.2–6 Adverse effects (AEs) are frequent, and interruption is sometimes needed in patients aged 60 and older, even those receiving
low-dose treatment. Observing that lesions continued to heal during withdrawal, it was decided to evaluate the safety and efficacy of an intermittent low-dose meglumine antimonate (MA) regimen for ATL in the elderly. 2030-01-01